Mo Qatanani joined Scholar Rock in 2021 and has served as Chief Scientific Officer since 2024. He is responsible for all research functions, including discovery biology, protein sciences & antibody engineering, safety and translational sciences. Mo brings more than 15 years of discovery and translational research experience in developing and advancing multiple therapeutic modalities across many disease areas in the biotech and pharmaceutical industry. Prior to Scholar Rock, Mo was a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Prior to Dyne, Mo held research positions of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.
Mo Qatanani, Ph.D.
Chief Scientific Officer